Literature DB >> 18250952

Striatal output markers do not alter in response to circling behaviour in 6-OHDA lesioned rats produced by acute or chronic administration of the monoamine uptake inhibitor BTS 74 398.

E L Lane1, S Cheetham, P Jenner.   

Abstract

The monoamine uptake inhibitor BTS 74 398 induces ipsilateral circling in 6-hydroxydopamine (6-OHDA) lesioned rats without induction of abnormal motor behaviours associated with L-dopa administration. We examined whether this was reflected in the expression of peptide mRNA in the direct and indirect striatal output pathways.6-OHDA lesioning of the nigrostriatal pathway increased striatal expression of PPE-A mRNA and decreased levels of PPT mRNA with PPE-B mRNA expression remaining unchanged. Acute L-dopa administration normalised PPE-A mRNA and elevated PPT mRNA while PPE-B mRNA expression remained unchanged. Acute administration of BTS 74 398 did not alter striatal peptide mRNA levels. Following chronic treatment with L-dopa, PPE-A mRNA expression in the lesioned striatum continued to be normalised and PPT mRNA was increased compared to the intact side. PPE-B mRNA expression was also markedly increased relative to the non-lesioned striatum. Chronic BTS 74 398 administration did not alter mRNA expression in the 6-OHDA lesioned striatum although small increases in PPT mRNA expression in the intact and sham lesioned striatum were observed. The failure of BTS 74 398 to induce changes in striatal neuropeptide mRNA correlated with its failure to induce abnormal motor behaviours or behavioural sensitisation but does not explain how it produces a reversal of motor deficits. An action in another area of the brain appears likely and may explain the subsequent failure of BTS 74 398 and related compounds to exert anti-parkinsonian actions in man.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18250952     DOI: 10.1007/s00702-007-0854-x

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  40 in total

1.  Differential regional effects of long-term L-DOPA treatment on preproenkephalin and preprotachykinin gene expression in the striatum of 6-hydroxydopamine-lesioned rat.

Authors:  P Salin; G Dziewczapolski; O S Gershanik; A Nieoullon; R Raisman-Vozari
Journal:  Brain Res Mol Brain Res       Date:  1997-07

2.  Repeated administration of the monoamine reuptake inhibitor BTS 74 398 induces ipsilateral circling in the 6-hydroxydopamine lesioned rat without sensitizing motor behaviours.

Authors:  E L Lane; S C Cheetham; P Jenner
Journal:  Eur J Neurosci       Date:  2005-01       Impact factor: 3.386

3.  Dopaminergic regulation of striatonigral tachykinin and dynorphin gene expression: a study with the dopamine uptake inhibitor GBR-12909.

Authors:  S P Sivam
Journal:  Brain Res Mol Brain Res       Date:  1996-01

4.  Behavioral and anatomical effects of long-term L-dihydroxyphenylalanine (L-DOPA) administration in rats with unilateral lesions of the nigrostriatal system.

Authors:  Anna Mura; Matti Mintz; Joram Feldon
Journal:  Exp Neurol       Date:  2002-09       Impact factor: 5.330

5.  Pharmacological validation of behavioural measures of akinesia and dyskinesia in a rat model of Parkinson's disease.

Authors:  M Lundblad; M Andersson; C Winkler; D Kirik; N Wierup; M Angela Cenci
Journal:  Eur J Neurosci       Date:  2002-01       Impact factor: 3.386

6.  Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.

Authors:  B Henry; A R Crossman; J M Brotchie
Journal:  Exp Neurol       Date:  1999-02       Impact factor: 5.330

7.  L-DOPA reverses altered gene expression of substance P but not enkephalin in the caudate-putamen of common marmosets treated with MPTP.

Authors:  J Jolkkonen; P Jenner; C D Marsden
Journal:  Brain Res Mol Brain Res       Date:  1995-09

8.  Neonatal and adult 6-hydroxydopamine-induced lesions differentially alter tachykinin and enkephalin gene expression.

Authors:  S P Sivam; G R Breese; J E Krause; T C Napier; R A Mueller; J S Hong
Journal:  J Neurochem       Date:  1987-11       Impact factor: 5.372

9.  The monoamine reuptake inhibitor BTS 74 398 fails to evoke established dyskinesia but does not synergise with levodopa in MPTP-treated primates.

Authors:  Matthew J Hansard; Lance A Smith; Michael J Jackson; Sharon C Cheetham; Peter Jenner
Journal:  Mov Disord       Date:  2004-01       Impact factor: 10.338

10.  Chronic L-dopa treatment in the unilateral 6-OHDA rat: evidence for behavioral sensitization and biochemical tolerance.

Authors:  R J Carey
Journal:  Brain Res       Date:  1991-12-24       Impact factor: 3.252

View more
  1 in total

Review 1.  Monoamine reuptake inhibitors in Parkinson's disease.

Authors:  Philippe Huot; Susan H Fox; Jonathan M Brotchie
Journal:  Parkinsons Dis       Date:  2015-02-25
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.